Craniopharyngioma With Tumoral Hemorrhage

NCT ID: NCT04937335

Last Updated: 2021-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

185 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-01

Study Completion Date

2021-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical data of 185 consecutive patients receiving resective operation with a pathological diagnosis of craniopharyngioma in our hospital between January 2013 and February 2021 were collected. Among these patients, 18 of them were recognized as craniopharyngioma with tumoral hemorrhage during the operation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For each case, age, gender, smoking status, alcohol intake, past history, symptoms, blood pressure, blood cell count, blood biochemical tests, coagulation tests, hormone tests, radiological results, surgical treatment and the outcome at discharge were collected. The first test result after admission and before the operation was taken for the items of blood tests with multiple times in the analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Craniopharyngioma Apoplexy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-hemorrhage group

Patients recognized as craniopharyngioma pathologically without tumoral hemorrhage observed during the operation

No interventions assigned to this group

Hemorrhage group

Patients recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation

intratumoral hemorrhage

Intervention Type OTHER

Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intratumoral hemorrhage

Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* receive resective operation with a pathological diagnosis of craniopharyngioma in our hospital
* enter our hospital between January 2013 and February 2021

Exclusion Criteria

* have a non-craniopharyngioma or unverified pathological diagnosis at discharge
* have received surgical or radiological treatment on the sellar region
* receive treatment of coagulation modulation, immunosuppressive agents or chemotherapeutic drugs
* combine with other clinical emergencies including acute myocardial infarction, cerebral stroke, trauma and sepsis at admission
* have been diagnosed with other tumors, hematological diseases, autoimmune diseases, liver failure or renal failure
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tongji Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kai Shu

Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kai Shu, MD

Role: STUDY_DIRECTOR

Tongji Hospital

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

kaishu1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Aggressive Spinal Hemangioma
NCT06996873 NOT_YET_RECRUITING